Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-2173 DDI Study with Midazolam or Clarithromycin in Healthy Subjects
NCT05137600Phase 1Completed
- Sponsor
- Antios Therapeutics
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ATI-2173 in hepatitis B (HBV) (2 arms), sponsored by Antios Therapeutics. Primary endpoints: Maximum Plasma Concentration (Cmax) of Midazolam at 3 months, Area Under the Plasma Concentration-Time Curve from Time Zero to Time t (AUC0-t) of Midazolam at 3 months and 3 more. Started Oct 2021; status: completed.
02
Drugs
ATI-2173
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT05137600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05137600.